HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
BIOBOARD - CANADA
Genome British Columbia researchers closing in on chlamydia vaccine

Chlamydia is one of the most widespread sexually transmitted bacterial diseases in the world, causing an estimated 92 million infections globally per year. With existing treatment programs failing to stem the spread of infection, a vaccine is widely acknowledged as the only way to prevent the suffering and significant infertility caused by Chlamydia (C. trachomatis), the causative agent for the disease.

Recent advances in mass spectrometry technology, proteomics, genomics and Chlamydia immunology have resulted in significant advancements towards vaccine development. Through its Proof-of-Concept (POC) program Genome British Columbia (Genome BC) is funding the necessary pre-clinical studies to move a novel Chlamydia vaccine to human trials.

Genome British Columbia is a catalyst for the life sciences cluster on Canada's West Coast.

"Investment into public health is of significant importance to our province," says Dr. Alan Winter, President and CEO of Genome BC. "Genome BC remains committed to funding research that will result in practical, societal benefits and these projects demonstrate that."

Dr. Robert Brunham of the BC Centre for Disease Control is leading the POC project entitled "Accelerating the Development of a Novel Outer Membrane Protein Based Vaccine Against Chlamydia Infection". The project, in partnership with the Canadian not-for-profit Pan-Provincial Vaccine Enterprise Inc. (PREVENT), is expected to run over 21 months and will also include US Food and Drug Administration filings for anticipated clinical grade vaccine production.

The market profile for a Chlamydia vaccine is expected to be similar to the HPV vaccine currently on the market, which is now part of publicly funded healthcare and beginning to reduce HPV rates among Canadians.

Source: Marketwired News

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy